The global market for human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics is competitive in nature and is projected to witness a high level of competition in the next few years, states a new market research study by Transparency Market Research. Some of the key players operating in the market across the globe are Roche AG, Valeant Pharmaceuticals, Perrigo Company plc, Clinigen Group plc., Fougera Pharmaceuticals, and Fresenius Kabi USA. Among the mentioned players, the Roche AG is estimated to account for a large share of the cytomegalovirus therapeutics market and Valeant Pharmaceuticals is projected to lead the human papillomavirus therapeutics market in the coming few years. The rising focus on research and development activities is projected to enhance the growth of the overall market in the next few years.
According to the market intelligence study by Transparency Market Research, in 2012, the global market for human papillomavirus (HPV) therapeutics market was worth US$1.40 bn and is projected to reach a value of US$2.34 bn by the end of 2020. The market is estimated to register a healthy 7.7% CAGR between 2014 and 2020. Furthermore, in 2012, the global market for cytomegalovirus (CMV) therapeutics market was worth US$870.1 mn and is projected to reach a value of US$922.8 mn by the end of 2020. The market is estimated to register a 1.49 % CAGR between 2014 and 2020.
Request A Sample-
South America and Asia Pacific to Witness High Growth in Coming Years
The global market for HPV and CMV therapeutics has been categorized on the basis of geography into the Middle East and Africa, North America, South America, Europe and Asia Pacific. At present, Asia Pacific and South America are expected to witness high growth throughout the forecast period.